These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31261181)

  • 1. A personal account of depressive illness and its antidepressant treatment.
    Baldwin DS
    Int Clin Psychopharmacol; 2019 Nov; 34(6):286-290. PubMed ID: 31261181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].
    Leblé N; Radon L; Rabot M; Godart N
    Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users.
    Bot M; Milaneschi Y; Penninx BW; Drent ML
    Psychoneuroendocrinology; 2016 Jun; 68():148-55. PubMed ID: 26974499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.
    Saveanu R; Etkin A; Duchemin AM; Goldstein-Piekarski A; Gyurak A; Debattista C; Schatzberg AF; Sood S; Day CV; Palmer DM; Rekshan WR; Gordon E; Rush AJ; Williams LM
    J Psychiatr Res; 2015 Feb; 61():1-12. PubMed ID: 25586212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating partial responders to antidepressant treatment.
    Trivedi MH
    J Clin Psychiatry; 2009 Sep; 70(9):e31. PubMed ID: 19818237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
    Kircanski K; Williams LM; Gotlib IH
    Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antidepressant use between subjects with bipolar disorder and major depressive disorder with or without comorbid anxiety.
    Schaffer A; Cairney J; Veldhuizen S; Cheung A; Levitt A
    J Clin Psychiatry; 2007 Nov; 68(11):1785-92. PubMed ID: 18052573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment.
    Gaspersz R; Lamers F; Kent JM; Beekman ATF; Smit JH; van Hemert AM; Schoevers RA; Penninx BWJH
    J Psychiatr Res; 2017 Jan; 84():41-48. PubMed ID: 27693981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical differences between early and late remission in depressive patients.
    Roca M; García-Toro M; García-Campayo J; Vives M; Armengol S; García-García M; Asensio D; Gili M
    J Affect Disord; 2011 Nov; 134(1-3):235-41. PubMed ID: 21676465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for treatment-resistant depression.
    Ballas C; Staab JP; Evans DL
    Psychopharmacol Bull; 2002; 36(4):39-62. PubMed ID: 12858144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
    Arnow BA; Blasey C; Williams LM; Palmer DM; Rekshan W; Schatzberg AF; Etkin A; Kulkarni J; Luther JF; Rush AJ
    Am J Psychiatry; 2015 Aug; 172(8):743-50. PubMed ID: 25815419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics.
    Sowa NA; Bengtson A; Gaynes BN; Pence BW
    J Affect Disord; 2016 Mar; 192():153-61. PubMed ID: 26724694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder.
    Iosifescu DV; Bankier B; Fava M
    Curr Psychiatry Rep; 2004 Jun; 6(3):193-201. PubMed ID: 15142472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological approaches to the treatment of residual symptoms.
    Fava M
    J Psychopharmacol; 2006 May; 20(3 Suppl):29-34. PubMed ID: 16644769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of patient experience and its influence on adherence to antidepressant treatment.
    Johnston BJ
    J Psychosoc Nurs Ment Health Serv; 2013 Dec; 51(12):29-37. PubMed ID: 24102841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A personal account of reducing and stopping antidepressant treatment.
    Baldwin DS
    Int Clin Psychopharmacol; 2020 Jul; 35(4):194-200. PubMed ID: 32324612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Doxepin hydrochloride. Clinical value of this new thymoanaleptic agent].
    Richou H; Hug R
    Nouv Presse Med; 1972 Jun; 1(25):1717-8. PubMed ID: 5041723
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.